Journal of Shandong University (Health Sciences) ›› 2021, Vol. 59 ›› Issue (6): 33-37.doi: 10.6040/j.issn.1671-7554.0.2021.0481

Previous Articles     Next Articles

Progress in glucocorticoid-induced osteoporosis

CHEN Shihong   

  1. Department of Endocrinology, The Second Hospital of Shandong University, Jinan 250033, Shandong, China
  • Published:2021-06-10

Abstract: Glucocorticoids are widely used in the treatment of allergic and autoimmune diseases. Glucocorticoid-induced osteoporosis(GIOP)is one of the adverse reactions of long-term application of glucocorticoids, which is characterized by continuous decrease of bone formation accompanied by increase of bone resorption, leading to increased incidence of fracture and bringing serious harm to patients. Herein, we review the pathogenesis of GIOP and its prevention and treatment drugs, in order to raise the attention of clinicians to GIOP.

Key words: Glucocorticoids, Osteoporosis, Osteoblast, Osteoclast

CLC Number: 

  • R574
[1] 张学武, 姚海红, 梅轶芳, 等. 全国多中心使用糖皮质激素风湿病患者骨质疏松调查[J]. 中华临床免疫和变态反应杂志, 2017, 11(3): 277-284. ZHANG Xuewu, YAO Haihong, MEI Yifang, et al. Survey on glucocorticosteriod associated osteoporosis in patients with rheumatic diseases in China 2013[J]. Chinese Journal of Allergy and Clinical Immunology, 2017, 11(3): 277-284.
[2] Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis [J]. Arthrit Rheumatol, 2017, 69(8): 1521-1537.
[3] 中国医师协会风湿免疫科医师分会,中华医学会风湿病学分会,中华医学会骨质疏松和骨矿盐疾病分会,等. 2020版中国糖皮质激素性骨质疏松症防治专家共识[J]. 中华内科杂志, 2021, 60(1): 13-21.
[4] Lane NE. Glucocorticoid-induced osteoporosis: new insights into the pathophysiology and treatments [J]. Curr Osteoporos Rep, 2019, 17(1): 1-7.
[5] Hartmann K, Koenen M, Schauer S, et al. Molecular actions of glucocorticoids in cartilage and bone during health, disease, and steroid therapy [J]. Physiol Rev, 2016, 96(2): 409-447.
[6] Hachemi Y, Rapp AE, Picke AK, et al. Molecular mechanisms of glucocorticoids on skeleton and bone regeneration after fracture [J]. J Mol Endocrinol, 2018, 61(1): R75-R90.
[7] Yang YJ, Zhu Z, Wang DT, et al. Tanshinol alleviates impaired bone formation by inhibiting adipogenesis via KLF15/PPARgamma2 signaling in GIO rats [J]. Acta Pharmacol Sin, 2018, 39(4): 633-641.
[8] Han L, Wang B, Wang R, et al. The shift in the balance between osteoblastogenesis and adipogenesis of mesenchymal stem cells mediated by glucocorticoid receptor [J]. Stem Cell Res Ther, 2019, 10(1): 377.
[9] Zanotti S, Yu J, Adhikari S, et al. Glucocorticoids inhibit notch target gene expression in osteoblasts [J]. J Cell Biochem, 2018, 119(7): 6016-6023.
[10] Deng S, Dai G, Chen S, et al. Dexamethasone induces osteoblast apoptosis through ROS-PI3K/AKT/GSK3β signaling pathway [J]. Biomed Pharmacother, 2019, 110: 602-608. doi: 10.1016/j.biopha.2018.11.103.
[11] Lian W, Ko J, Chen Y, et al. Chaperonin 60 sustains osteoblast autophagy and counteracts glucocorticoid aggravation of osteoporosis by chaperoning RPTOR [J]. Cell Death Dis, 2018, 9(10): 938.
[12] Wang T, Liu X, He C. Glucocorticoid-induced autophagy and apoptosis in bone [J]. Apoptosis, 2020, 25(3-4): 157-168.
[13] Fu L, Wu W, Sun X, et al. Glucocorticoids enhanced osteoclast autophagy through the PI3K/Akt/mTOR signaling pathway [J]. Calcif Tissue Int, 2020, 107(1): 60-71.
[14] Conaway HH, Henning P, Lie A, et al. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity [J]. Bone, 2016, 93: 43-54. doi: 10.1016/j.bone.2016.08.024.
[15] Li HX, Li DH, Ma ZM, et al. Defective autophagy in osteoblasts induces endoplasmic reticulum stress and causes remarkable bone loss [J]. Autophagy, 2018, 14(10): 1726-1741.
[16] Gan ZY, Fitter S, Vandyke K, et al. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma [J]. Eur J Haematol, 2015, 94(4): 343-354.
[17] Florez H, Hernández-Rodríguez J, Muxi A, et al. Trabecular bone score improves fracture risk assessment in glucocorticoid-induced osteoporosis [J]. Rheumatology, 2020, 59(7): 1574-1580.
[18] Chotiyarnwong P, McCloskey EV. Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment [J]. Nat Rev Endocrinol, 2020, 16(8): 437-447.
[19] Ding L, Hu J, Wang D, et al. Efficacy and safety of first- and second-line drugs to prevent glucocorticoid-induced fractures [J]. J Clin Endocrinol Metab, 2020, 105(1): dgz023. doi: 10.1210/clinem/dgz023.
[20] Matsumoto T, Yamamoto K, Takeuchi T, et al. Eldecalcitol is superior to alfacalcidol in maintaining bone mineral density in glucocorticoid-induced osteoporosis patients(e-GLORIA)[J]. J Bone Miner Metab, 2020, 38(4): 522-532.
[21] Adami G, Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review[J]. Osteoporos Int, 2019, 30(6): 1145-1156.
[22] Bergman J, Nordström A, Nordström P. Alendronate use and the risk of nonvertebral fracture during glucocorticoid therapy: a retrospective cohort study [J]. J Clin Endocrinol Metab, 2018, 103(1): 306-313.
[23] Kan S, Yuan Z, Li Y, et al. Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases [J]. Medicine(Baltimore), 2016, 95(25): e3990. doi: 10.1097/MD.0000000000003990.
[24] Lv F, Guan Y, Ma D, et al. Effects of alendronate and alfacalcidol on bone in patients with myasthenia gravis initiating glucocorticoids treatment [J]. Clin Endocrinol(Oxf), 2018, 88(3): 380-387.
[25] Saag KG, Pannacciulli N, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: final results of a twenty-four-month randomized, double-blind, double-dummy trial [J]. Arthritis Rheumatol, 2019, 71(7): 1174-1184.
[26] Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis [J]. Drug Des Devel Ther, 2019, 13: 2843-2852. doi:10.2147/DDDT.S148654.
[27] Taylor AD, Saag KG. Anabolics in the management of glucocorticoid-induced osteoporosis: an evidence-based review of long-term safety, efficacy and place in therapy [J]. Core Evid, 2019, 14: 41-50. doi: 10.2147/CE.S172820.
[28] Tanaka I, Tanaka Y, Soen S, et al. Efficacy of once-weekly teriparatide in patients with glucocorticoid-induced osteoporosis: the TOWER-GO study [J]. J Bone Miner Metab, 2021, 39(3): 446-455.
[29] Chandler H, Brooks DJ, Hattersley G, et al. Abaloparatide increases bone mineral density and bone strength in ovariectomized rabbits with glucocorticoid-induced osteopenia [J]. Osteoporos Int, 2019, 30(8): 1607-1616.
[30] Yoon SH, Grynpas MD, Mitchell J. Growth hormone increases bone toughness and decreases muscle inflammation in glucocorticoid-treated Mdx mice, model of duchenne muscular dystrophy [J]. J Bone Miner Res, 2019, 34(8): 1473-1486.
[31] Sato AY, Cregor M, McAndrews K, et al. Glucocorticoid-induced bone fragility is prevented in female mice by blocking Pyk2/Anoikis signaling [J]. Endocrinology, 2019, 160(7): 1659-1673.
[32] Ren H, Yu X, Shen G, et al. miRNA-seq analysis of human vertebrae provides insight into the mechanism underlying GIOP [J]. Bone, 2019, 120: 371-386.doi: 10.1016/j.bone.2018.11.013.
[33] Shen G, Ren H, Shang Q, et al. Let-7f-5p regulates TGFBR1 in glucocorticoid-inhibited osteoblast differentiation and ameliorates glucocorticoid-induced bone loss [J]. Int J Biol Sci, 2019, 15(10): 2182-2197.
[34] Colditz J, Thiele S, Baschant U, et al. Osteogenic Dkk1 mediates glucocorticoid-Induced but not arthritis-induced bone loss [J]. J Bone Miner Res, 2019, 34(7): 1314-1323.
[35] Farasat Zaman YZBC. Humanin is a novel regulator of Hedgehog signaling and prevents glucocorticoid-induced bone growth impairment [J]. FASEB J, 2019, 33(4): 4962-4974.
[1] CHEN Shihong, JIANG Dongqing, ZHUANG Xianghua, LI Xiaobo, PAN Zhe, SUN Aili, LOU Nengjun, WANG Dianhui, DU Jiaojiao, SONG Yuwen. Primary biliary cholangitis with bone pain as the main manifestation: a case report [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 98-102.
[2] LYU Li, JIANG Lu, CHEN Shihong, ZHUANG Xianghua, SONG Yuwen, WANG Dianhui, AN Wenjuan, LI Qian, PAN Zhe. Related factors of osteoporosis in 210 postmenopausal women with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 19-25.
[3] Ping LIU,Yuwen SONG,Ping WANG,Guangwei TIAN,Fengjie ZHENG,Li LYU,Jiaojiao DU,Jing ZHANG,Xianghua ZHUANG,Shihong CHEN. Correlation between vitamin D deficiency and depression in patients with type 2 diabetes mellitus [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 51-56,102.
[4] LUO Xianghang, ZHOU Ruoyu. Advances on the etiology and pathogenesis of osteoporosis [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 10-14.
[5] CHENG Xiaoguang, LU Yanhui. Osteoporosis in men: a chronically overlooked problem [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 5-9.
[6] XING Xiaoping. Diagnosis and management of primary osteoporosis [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 1-4.
[7] Jiaojiao DU,Xianghua ZHUANG,Shihong CHEN,Xuemeng WANG,Dongqing JIANG,Fei WU,Xiaolin HAN,Mengyu HUA,Yuwen SONG. Changes of serum IL-31 and IL-33 levels in postmenopausal patients with osteoporosis [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 45-50.
[8] LI Minqi, DU Juan, YANG Panpan, KOU Yuying, LIU Shanshan. Research progress of oxidative stress regulating osteoporosis [J]. Journal of Shandong University (Health Sciences), 2021, 59(6): 16-24.
[9] KANG Chengwei, LIU Lei, PU Xiaobing, TAN Gang, DONG Changchao, YAN Zhaokui. Analysis of bone metabolism and bone turnover markers in 62 cases of osteoporosis with subclinical hypothyroidism [J]. Journal of Shandong University (Health Sciences), 2020, 58(5): 82-86.
[10] LI Na, ZHANG Zhimian. Correlation of vascular calcification indicators in 138 patients aged between 39 and 81 years [J]. Journal of Shandong University (Health Sciences), 2020, 58(2): 85-89.
[11] JI Yuanyuan, BAO Jingbo, ZHAO Xu, CAO Luning, CUI Min, ZHANG Na, YU Lingzhi. IL-17F promotes the proliferation, mineralization and expressions of Runx2 and Osterix in rat osteoblasts [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(8): 24-29.
[12] XU Daxia, HOU Nan, LI Xiaofeng, WANG Chuang, KONG Meng, JIAO Guangjun, CHEN Yunzhen. Relevance between bone metabolism of glucocorticoid-induced osteoporosis and duration of glucocorticoid treatment [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 103-107.
[13] PENG Fei, SONG Ling, QI Xiangmin, LI Yaqin, DIAO Yanfei, ZHAO Shoufeng, WANG Lili, YANG Fang, LU Shulai, LÜ Wenfang, GUO Dawei. Intermittent tensile stress affects the expression of TRPV5 in murine osteoclasts [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(11): 22-26.
[14] FENG Xiaoyu, ZHANG Hongmei, CHE Xuanqiang, KANG Donghong. Therapeutic effects of human osteoblast-stimulating factor on osteoporosis of ovariectomized rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2015, 53(7): 8-12.
[15] DI Jing, SHI Xiaoting, LI Xue, LIN Zhiyong, SUN Zhe, DENG Fengying. Effect of parathyroid hormone1-34 on bone healing around dental implants in ostoeporotic rats [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(8): 22-26.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] SHI Shuang, LI Juan, MI Qi, WANG Yunshan, DU Lutao, WANG Chuanxin. Construction and application of a miRNAs prognostic risk assessment model of gastric cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 47 -52 .
[2] LYU Longfei, LI Lin, LI Shuhai, QI Lei, LU Ming, CHENG Chuanle, TIAN Hui. Application of laparoscopic fine needle catheter jejunostomy in minimally invasive McKeown resection of esophageal cancer[J]. Journal of Shandong University (Health Sciences), 2020, 1(7): 77 -81 .
[3] SHAO Haigang, WANG Xuan, WANG Qing. Anatomy of the root canal system of mandibular first premolar in population of Shandong Province[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(9): 85 -89 .
[4] LIU Hai-Chun, ZHANG Jian-Feng, CHEN Yuan-zhen. Bone collagen and biomechanical propertyies in the femur of osteoporosis rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(5): 42 -45 .
[5] FENG Fuli1, WEI Shuzhen2, ZHANG Yonghuan3, LI Li1, CHEN Rong1, LIRuifeng1. Relationship between high mortality and altered expression of Klotho in insulin resistance rats[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2010, 48(6): 5 -8 .
[6] TANG Fang1,2, ZHANG Yingqian3, WANG Zhiqiang4, KANG Dianmin4,
WANG Jiezhen1, XUE Fuzhong1
. A 2D minimal spanning tree model of the spatial structures of natural focal disease[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2009, 47(01): 106 -110 .
[7] LI Wei,LI Dao-wei,YE Qian,GAO Shun-cui,JIANG Shu-juan.

Diagnostic value of transbronchial needle aspiration in paratracheal mediastinal lesions

[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2008, 46(11): 1063 -1065 .
[8] ZHU Xiaoli1, GUO Shuling1, SU Lei1, FENG Yuxin2, YUAN Fangshu1. Extraction of total proteins from demodex and qualification of their molecular weights[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2014, 52(5): 58 -62 .
[9] LI Yu-liang,WANG Yong-zheng,WANG Xiao-hua,ZHANG Fu-jun,ZHU Li-dong,ZHANG Wang-ming,LI Zheng,LI Zhen-jia,ZHANG Kai-xian. I implantation combined with Gemcitabine in the treatment of advanced pancreatic cancer[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2007, 45(4): 393 -396 .
[10] WANG Xu-ping,ZHAO Ling,FENG Yu-xin,SHANG Lin-shan,LIU Jin-cheng,. [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2006, 44(6): 564 -567 .